"Two Court of Chancery Deal Litigation Decisions Provide Helpful Guidance"

by Skadden, Arps, Slate, Meagher & Flom LLP
Contact

Skadden, Arps, Slate, Meagher & Flom LLP

Chelsea Therapeutics: Post-Closing Bad Faith Claim a ‘Rare Bird’ in Delaware Absent Allegations of Self-Interestedness or Lack of Independence

In In re Chelsea Therapeutics International LTD Stockholders Litigation, Vice Chancellor Sam Glasscock III of the Delaware Court of Chancery dismissed claims that Chelsea Therapeutics International Ltd.’s (Chelsea) board of directors acted in bad faith by selling Chelsea to Lundbeck A/S (Lundbeck) at an amount substantially below its standalone value. Specifically at issue were the board’s instructions to its financial advisor to ignore one set of financial projections in opining on the fairness of the sale, as well as the board’s choice to disregard a second set of projections before recommending the transaction to Chelsea’s stockholders. The plaintiffs did not otherwise challenge the board members’ interests or independence but rather argued that such actions were “inconceivable as anything other than actions against the interests of the stockholders” and therefore must constitute bad faith. In dismissing the claims, the court noted that bad faith was a “rare bird,” further highlighting the difficulty stockholders of Delaware corporations face in bringing post-closing bad faith claims against otherwise unconflicted boards.

Background

Chelsea researched and developed a drug called Northera, which treated symptomatic neurogenic orthostatic hypotension (NOH). Prior to Northera’s Food and Drug Administration (FDA) approval, a market check had yielded no potential buyers. Following Northera’s approval, several potential buyers expressed a renewed interest in Chelsea, including Lundbeck. When negotiating the transaction, the Chelsea board had been reviewing and relying upon three sets of projections for the company. The “Base Case” assumed one possible application for Northera — the treatment of NOH. The “Adjusted Base Case” made the same assumption but reflected higher net sales due to an increase in Chelsea’s sales force. The “No-Midodrone Projections” assumed a hypothetical scenario where Northera’s competitor, Midodrone, would be removed from the market. None of the projections reflected results of a study that Chelsea had commissioned that analyzed potential revenue streams from applications of Northera that were not yet FDA approved.

Immediately after the transaction was announced, the plaintiffs sought a preliminary injunction to prevent the transaction from closing. The plaintiffs alleged, among other things, that the proxy was deficient because it omitted the No-Midodrone Projections and the results of the study analyzing potential uses for Northera. Although these projections were not disclosed, the proxy did disclose that the board had considered the No-Midodrone Projections and concluded they were too speculative and, thus, instructed the financial advisor not to take them into account. The court denied the injunction, finding that the projections and study were highly speculative and therefore the existing disclosures were sufficient.

The plaintiffs subsequently pursued a post-closing action for damages where they renewed their arguments regarding the purported disclosure violations and additionally claimed that Chelsea’s directors had breached their duty of loyalty by knowingly selling the company at a price substantially below its standalone value. The bad faith allegations mirrored the disclosure violations — specifically, that the directors had improperly instructed their financial advisors to exclude the No-Midodrone Projections when opining on the fairness of the transaction, and that the directors themselves had ignored the commissioned study when evaluating the company’s value, which indicated a higher value for the company. The plaintiffs argued that excluding these projections allowed the financial advisor to determine the transaction was fair when it was not and allowed the directors to recommend an inadequate price. The plaintiffs argued that there was no conceivable basis on which it was in the interest of the stockholders for the board and its financial advisors to exclude these projections, and that the directors, despite their independence and disinterestedness, “must have” acted in bad faith.

Court’s Analysis

Based on the record created at the preliminary injunction hearing, the court rejected the plaintiff’s disclosure violations, holding that the board did not have a duty to disclose the No-Midodrone Projections or results of the study (and their implications for value) due to their speculative nature.

In dismissing the bad faith claim on its merits, the court declined to reach the issue of whether a fully informed stockholder vote could cleanse bad faith board action under the holdings of Corwin v. KKR Financial Holdings LLC. Similarly, the court did not decide whether Corwin could apply in the context of a tender offer.

Rather, in its analysis, the court compared a bad faith claim to waste and noted that “like waste, [bad faith] is a rara avis.” The court explained that to state a bad faith claim, a plaintiff must plead either an “extreme set of facts” to show that “disinterested directors were intentionally disregarding their duties” or that “the decision under attack is so far beyond the bounds of reasonable judgment that it seems essentially inexplicable on any ground other than bad faith.” The court further noted that the plaintiffs relied “on the most difficult path to overcome dismissal of a claim based on bad faith: that the action complained of is otherwise inexplicable, so that bad faith — a motive other than the interest of the [c]ompany — must be at work.”

The court found that, contrary to the plaintiffs’ allegations, it was readily explicable that the board would exclude such highly speculative projections. The court reasoned that there were no assurances that Midodrone would be taken off the market or that Northera would be proven capable of treating additional conditions and then approved by the FDA for those uses. The court also noted that if the omitted projections would have reflected a realistic valuation, another bidder would have likely emerged throughout the 20-month-long sales process. Thus, the plaintiffs failed to plead facts that demonstrated the directors’ decision to disregard the projections was so egregious that it was reasonably conceivable the board acted in bad faith.

In re Books-A-Million, Inc. Stockholders Litigation: Delaware Court of Chancery Applies ‘MFW’ Framework to Going-Private Transaction and Dismisses Claims on Motion to Dismiss

In his recent Books-A-Million opinion, Vice Chancellor J. Travis Laster of the Delaware Court of Chancery clarified the obligations of controlling stockholders in going-private transactions under the “MFW” framework. Noting that compliance with the MFW framework can be tested on a motion to dismiss, the court dismissed breach of fiduciary duty claims against the Books-A-Million board of directors and its controlling stockholders.

Background

Following an inquiry from a third party (identified in the proxy as Party Y), the controlling family stockholders (the Anderson Family) of Books-A-Million, Inc. (BAM) made a proposal to acquire the remaining minority shares for $2.75 per share, a 65 percent premium over the average closing price for the past 90 days. The proposal contemplated the formation of a special committee of independent directors with its own financial and legal advisers. The proposal also stated that the Anderson Family would not move forward with the transaction unless it was approved by a special committee and that any agreement would need to include a nonwaivable majority of the minority condition. The Anderson Family expressly stated that it was only interested in purchasing BAM’s minority shares and would not sell its shares to a third party.

In response to the Anderson Family proposal, the board formed a special committee (the Special Committee) consisting of the three BAM directors not affiliated with the Anderson Family. Shortly after retaining counsel, one member of the Special Committee, Ronald G. Bruno, disclosed that, even though he qualified as an independent director under Nasdaq rules, he had certain social and civic ties to the Anderson Family that may otherwise call his independence into question. The Special Committee and its counsel met later that same day (without Bruno in attendance) and determined that it would be preferable if Bruno did not serve on the Special Committee to avoid any possible challenges to its independence. Bruno resigned that same day and the Special Committee retained Houlihan Lokey to serve as its financial advisor.

In light of the Anderson Family’s plan to finance its proposal using the company’s existing credit facility, the Special Committee decided to evaluate alternative transaction structures. Houlihan Lokey also contacted three other entities despite the Anderson Family’s expressed intention not to sell any of their shares. Ultimately, only Party Y submitted an indication of interest at a price of $4.21 per share, conditioned on due diligence and other matters. Party Y also rejected the idea of making a minority investment, indicating that it was only interested in purchasing a controlling stake.

Recognizing that there was no viable path forward with Party Y, the BAM board determined to continue negotiations with the Anderson Family only. After several rounds of negotiations, the Anderson Family and the Special Committee agreed on $3.25 a share, with the Anderson Family maintaining a right to terminate the transaction if 10 percent or more of the minority stockholders sought to exercise their appraisal rights. On July 13, 2015, Houlihan Lokey delivered an opinion that the $3.25 per share contemplated by the family’s proposal was fair to minority stockholders from a financial point of view. The Special Committee and Bruno attended Houlihan Lokey’s presentation, and Bruno was subsequently excused during the Special Committee’s deliberations. The Special Committee members then deliberated and voted to recommend the Anderson Family’s offer to the full board.

The merger consideration valued the company’s minority interest at $21 million. The merger was financed through borrowings under the company’s credit facilities, and the company’s three top executives entered into rollover agreements. On October 22, 2105, BAM filed its definitive proxy statement, and the Anderson Family’s proposed buyout was submitted to BAM’s stockholders on December 8, 2015. Approximately 66.3 percent of the shares not affiliated with the Anderson Family or any Section 16 BAM officer approved the merger. The transaction closed on December 10, 2015.

Stockholder Litigation and Court’s Analysis

Following announcement of the transaction, the minority stockholders filed suit for breach of fiduciary duty against (i) the two members of the Special Committee, (ii) Bruno, as the resigned Special Committee member who later voted in favor of the transaction, (iii) the Anderson Family’s two board representatives, and (iv) the three members of BAM’s executive management who entered into the rollover agreements.

In reviewing the plaintiffs’ challenges to the BAM transaction, the court first noted that “compliance with the M&F Worldwide structure can be tested on a motion to dismiss.” Citing Swomley v. Schlecht,1 the court stated that “[i]f the defendants have described their adherence to the elements identified in M&F Worldwide ‘in a public way suitable for judicial notice, such as board resolutions and a proxy statement,’ then the court will apply the business judgment rule at the motion to dismiss stage unless the plaintiff has ‘pled facts sufficient to call into question the existence of those elements.’”

The court then turned to the plaintiffs’ specific allegations and held that they “do not support a reasonably conceivable inference that any of the M&F Worldwide conditions were not met,” and therefore the business judgment rule would apply. Taking each of the MFW elements in turn, Vice Chancellor Laster concluded as follows:

  • The Anderson Family conditioned the transaction ab initio upon the approval of an independent and empowered Special Committee and a nonwaivable majority of the minority stockholder vote. In so finding, the court rejected the plaintiffs’ argument that the Anderson Family’s 2015 proposal was a continuation of a prior offer made by the Anderson Family in 2012, which did not contain these minority protections. The complaint acknowledged that a special committee had previously rejected the 2012 offer, thereby terminating it.
  • The Special Committee was independent. The plaintiffs mounted two separate collateral attacks on the Special Committee’s independence. First, the plaintiffs alleged that Bruno was not independent from the Anderson Family and that he tainted the Special Committee’s independence by sitting in on Houlihan Lokey’s July 13, 2015, fairness opinion presentation. The court found, however, that Bruno’s early resignation from the Special Committee was a “commendable step for Bruno and the Committee to take,” and therefore, no decision needed to be made regarding his independence. The court so held notwithstanding Bruno’s presence during Houlihan Lokey’s presentation. Specifically, the court stated that “[u]nder different circumstances, the participation of a director whose independence was compromised might be problematic,” but “the allegations of the Complaint do not support a reasonably conceivable inference that having Bruno present solely for Houlihan Lokey’s fairness presentation prevents the Merger from meeting this element of the M&F Worldwide test.”

    Second, the plaintiffs alleged that the Special Committee acted in bad faith by refusing to continue negotiations with Party Y, which had previously offered up to $4.21 per share of BAM. The court first paused to consider whether a “good faith” requirement even existed under MFW and ultimately concluded that a pleading of “subjective bad faith is a theoretically viable means of attacking the M&F Worldwide framework.” Relying heavily on Mendel v. Carroll,2 however, the vice chancellor rejected the plaintiffs’ arguments holding that there could be no finding of bad faith where (i) the Anderson Family had no obligation to sell its controlling stake, and (ii) the Anderson Family did not overreach or exploit the minority in making its proposal. Under those circumstances, the court stated that “[u]nder the rule of Mendel, the Committee could not have acted loyally by deploying corporate power against the Anderson Family to facilitate a third party deal.”

  • The Special Committee was empowered to select its own advisers and say no definitively. Citing the proxy and BAM’s board resolutions, the court found that the Special Committee was granted the requisite authority to select its own advisers and further that the BAM board committed not to proceed with the transaction without a favorable recommendation from the Special Committee.
  • The Special Committee fulfilled its duty of care in negotiating a fair price. After noting that the standard of conduct for the duty of care remains gross negligence on a motion to dismiss, the court held that the Special Committee had fulfilled its duty by meeting 33 times over five months, seeking alternative buyers, considering alternative structures, rejecting the Anderson Family’s initial offer, negotiating over noneconomic terms and ultimately obtaining a sale price 20 percent higher than the Anderson Family’s initial offer.
  • The minority was informed and its vote was not coerced. The plaintiffs did not assert any disclosure claims and did not otherwise allege that the vote was coerced. Accordingly, the court found that the fifth and sixth MFW requirements were satisfied.

After determining that the transaction satisfied the elements of MFW, the court applied the business judgment rule and dismissed all causes of action with prejudice.

Implications

Chelsea Therapeutics and Books-A-Million add to a recent body of Delaware jurisprudence that narrows the path for plaintiffs to successfully pursue a post-closing damages case and indicate that courts are willing to dismiss lawsuits at the pleading stage.

Specifically, Chelsea Therapeutics indicates that when a company’s charter includes an exculpatory provision and there are no allegations of extreme facts, Delaware courts appear willing to dismiss conclusory bad faith claims when unaccompanied by specific allegations of interestedness or lack of independence.

Chelsea Therapeutics also confirms that plaintiffs continue to focus on disclosure of management projections and that there is no per se rule regarding their disclosure. Although the court determined that the specific omitted projections were not material, it also focused on their highly speculative characteristics and noted that such speculative nature was disclosed in the proxy. Accordingly, if a board is considering disclosing management projections, it should carefully determine whether the projections were actually relied upon and, if they were not, why they were not. If the board ultimately chooses not to rely on certain projections, strong consideration should be given as to whether the rationale for that decision should be documented and disclosed.

The Books-A-Million opinion confirms that Delaware courts are willing to apply the deferential business judgment rule where controlling stockholders seeking to take a company private heed the advice set forth by the Delaware Supreme Court in Kahn v. M&F Worldwide Corp., 88 A.3d 645 (Del. 2014). However, Books-A-Million suggests that controlling stockholders would be well advised to make even their initial offers conditioned upon both the approval of an independent and empowered special committee and nonwaivable majority of the minority vote.

Books-A-Million also confirms that Delaware courts will consider application of the MFW framework on a motion to dismiss provided that the transaction documents sufficiently describe the transaction’s compliance with each of the six MFW elements. Specifically, documents subject to judicial notice, including proxy statements and board resolutions, should be reviewed not only for compliance with state and federal disclosure laws but also for their descriptions of the company’s and interested parties’ adherence to the elements identified in M&F Worldwide.

_______________

1 2014 WL 4470947, at *20 (Del. Ch. Aug. 27, 2014) (TRANSCRIPT), aff’d 128 A.3d 992 (Del. 2015) (TABLE).

2 651 A.2d 297 (Del. Ch. 1994).

Download PDF

Written by:

Skadden, Arps, Slate, Meagher & Flom LLP
Contact
more
less

Skadden, Arps, Slate, Meagher & Flom LLP on:

Readers' Choice 2017
Reporters on Deadline

Related Case Law

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.